Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Coffers Fill With Funds, But No Money For Reagan-Udall Or Lab Closures

Executive Summary

FDA enters 2008 with the financial wherewithal to go full speed ahead in hiring and establishing the safety programs authorized by the FDA Amendments Act, following President Bush's signing of an omnibus fiscal 2008 appropriations package on Dec. 26

You may also be interested in...

Increased FDA China Inspections Backed By House Panel, While Purse Strings Pulled Still Tighter

Funds for the Reagan-Udall Foundation must come from the FDA commissioner’s office account, under successful amendment from Rep. DeLauro.

Reagan-Udall, Still Waiting For FDA Funding, Studies Drug Toxicity Pathways

Created by Congress to help FDA modernize medical product development and evaluation, the foundation will receive its first influx of federal money to support overhead in fiscal 2012.

FDA Post-Market Safety Efforts Won’t Be Impacted By Sentinel In Near Term

FDA's Sentinel post-market safety monitoring project will augment, not replace, the agency's current repertoire of post-market activities and requirements for drugs, Center for Drug Evaluation and Research Director Janet Woodcock emphasized

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts